Peptide Knowledge Base · Longevity

Rapamycin: what it is, what the evidence says, and its real status

Not a peptide, the longevity field's most-studied mTOR inhibitor, with strong animal lifespan data and growing human interest.

Can you actually get it?

Plain-English verdict: Join waitlist.

Regulatory status: 503A eligible.

How does Rapamycin work?

An mTOR inhibitor that, intermittently dosed, is proposed to mimic some benefits of caloric restriction.

What it does — and what it does not do

What it does: Studied for longevity and immune-aging; shows lifespan extension across many animal models.

What it does not do: Human lifespan benefit is not proven, and it is not a peptide.

How honest is the evidence?

Evidence grade B — Good human evidence.

robust animal lifespan data; human longevity outcomes still emerging

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Optimal dose/interval for longevity in humans, and long-term immune effects, are unresolved.

WADA status: Not prohibited.

How it is taken

Clinician-set; typically intermittent oral. Educational only.

Who should not take it

Immunosuppressive; caution with infections, wound healing, and metabolic markers. Clinician-supervised.

Sources

Rapamycin / mTOR lifespan literature · ongoing human longevity trials

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.